Log In
Print
BCIQ
Print
Print this Print this
 

IL-17A inhibitor Ensemblin (E-036041)

  Manage Alerts
Collapse Summary General Information
Company Ensemble Therapeutics Corp.
DescriptionSmall molecule macrocyclic IL-17A antagonist identified using Ensemblin technology
Molecular Target Interleukin-17A (IL-17A)
Mechanism of ActionInterleukin-17 (IL-17) antagonist
Therapeutic ModalityMacrocycle
Latest Stage of DevelopmentPreclinical
Standard IndicationArthritis
Indication DetailsTreat arthritis
Regulatory Designation

Partner

Novartis AG


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today